Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: A preliminary study

Experimental and Clinical Psychopharmacology

Volumn 20, Issue 3, 2012, Pages 181-190

  Bujarski, Spencer ^a   MacKillop, James ^b   Ray, Lara A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Alcohol; Asian Americans; Behavioral economics; Naltrexone

Indexed keywords

ALCOHOL; NALTREXONE; PLACEBO; MU OPIATE RECEPTOR; NARCOTIC ANTAGONIST; OPRM1 PROTEIN, HUMAN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ASIAN AMERICAN; BEHAVIORAL ECONOMICS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ELASTICITY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENOTYPE; HOMOZYGOTE; HUMAN; MALE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; ADDICTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRINKING BEHAVIOR; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; PSYCHOLOGICAL ASPECT; STATISTICAL MODEL;

ADULT; ALCOHOL DRINKING; ASIAN AMERICANS; BEHAVIOR, ADDICTIVE; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; GENOTYPE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MODELS, ECONOMIC; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, MU;

EID: 84867913402     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0027379     Document Type: Article

References (68)

1. Allen, J. P., Litten, R. Z., Fertig, J. B., & Babor, T. (1997). A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcoholism, Clinical and Experimental Research, 21, 613-619. doi: 10.1111/j.1530-0277.1997.tb03811.x.
2. Anton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., & Moak, D. (2004). Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: Temporal effects of drinking. Psychopharmacology (Berl), 173, 32-40. doi:10.1007/s00213-003-1720-7.
3. Anton, R. F., Moak, D. H., Waid, L. R., Latham, P. K., Malcolm, R. J., & Dias, J. K. (1999). Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. American Journal of Psychiatry, 156, 1758-1764.
4. Anton, R. F., O'Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Zweben, A. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. Journal of the American Medical Association, 295, 2003-2017. doi:10.1001/jama.295.17.2003.
5. Anton, R. F., Oroszi, G., O'Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008). An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry, 65, 135-144. doi:10.1001/archpsyc.65.2.135.
6. Arias, A., Feinn, R., & Kranzler, H. R. (2006). Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: A meta-analysis. Drug and Alcohol Dependence, 83, 262-268. doi:10.1016/j.drugalcdep.2005.11.024.
7. Balldin, J., Berglund, M., Borg, S., Mansson, M., Bendtsen, P., Franck, J., Willander, A. (2003). A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcoholism, Clinical and Experimental Research, 27, 1142-1149. doi:10.1097/01.ALC.0000075548.83053.A9.
8. Bickel, W. K., Marsch, L. A., & Carroll, M. E. (2000). Deconstructing relative reinforcing efficacy and situating the measures of pharmacological reinforcement with behavioral economics: a theoretical proposal. [Research Support, U.S. Gov't, P.H.S. Review]. Psychopharmacology, 153, 44-56.
9. Bickel, W. K., Miller, M. L., Yi, R., Kowal, B. P., Lindquist, D. M., & Pitcock, J. A. (2007). Behavioral and neuroeconomics of drug addiction: Competing neural systems and temporal discounting processes. Drug and Alcohol Dependence, 90 (Supp 1), S85-S91. doi:10.1016/j.drugalcdep.2006.09.016.
10. Bond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Yu, L. (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proceedings of the National Academy of Sciences of the United States of America, 95, 9608-9613. doi:10.1073/pnas.95.16.9608.
11. Chick, J., Anton, R., Checinski, K., Croop, R., Drummond, D. C., Farmer, R., Ritson, B. (2000). A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol and Alcoholism, 35, 587-593. doi:10.1093/alcalc/35.6.587.
12. Del Boca, F. K., Kranzler, H. R., Brown, J., & Korner, P. F. (1996). Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcoholism, Clinical and Experimental Research, 20, 1412-1417. doi:10.1111/j.1530-0277.1996.tb01142.x.
13. Drobes, D. J., Anton, R. F., Thomas, S. E., & Voronin, K. (2003). A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: Naltrexone and nalmefene. Neuropsychopharmacology, 28, 755-764. doi:10.1038/sj.npp.1300101.
14. Drobes, D. J., Anton, R. F., Thomas, S. E., & Voronin, K. (2004). Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcoholism, Clinical and Experimental Research, 28, 1362-1370. doi:10.1097/01.ALC.0000139704.88862.01.
15. Gelernter, J., Gueorguieva, R., Kranzler, H. R., Zhang, H., Cramer, J., Rosenheck, R., & Krystal, J. H. (2007). Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: Results from the VA Cooperative Study. Alcoholism, Clinical and Experimental Research, 31, 555-563.
16. Goldman, D., & Ducci, F. (2007). Deconstruction of vulnerability to complex diseases: Enhanced effect sizes and power of intermediate phenotypes. ScientificWorldJournal, 7, 124-130. doi:10.1100/tsw.2007.210.
17. Guardia, J., Caso, C., Arias, F., Gual, A., Sanahuja, J., Ramirez, M., Casas, M. (2002). A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: Results from a multicenter clinical trial. Alcoholism, Clinical and Experimental Research, 26, 1381-1387. doi:10.1111/j.1530-0277.2002.tb02682.x.
18. Heinala, P., Alho, H., Kiianmaa, K., Lonnqvist, J., Kuoppasalmi, K., & Sinclair, J. D. (2001). Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 21, 287-292. doi:10.1097/00004714-200106000-00006.
19. Hernandez-Avila, C. A., Covault, J., Wand, G., Zhang, H., Gelernter, J., & Kranzler, H. R. (2007). Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenetics and Genomics, 17, 1031-1038. doi: 10.1097/FPC.0b013e3282f0b99c.
20. Hitsman, B., MacKillop, J., Lingford-Hughes, A., Williams, T. M., Ahmad, F., Adams, S., Munafo, M. R. (2008). Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. Psychopharmacology (Berl), 196, 611-621. doi:10.1007/s00213-007-0995-5.
21. Hursh, S. R., Galuska, C. M., Winger, G., & Woods, J. H. (2005). Addictive drugs, effective therapies: It's all about the economy! Molecular Interventions, 5, 20-28. doi:10.1124/mi.5.1.6.
22. Hursh, S. R., & Silberberg, A. (2008). Economic demand and essential value. [Research Support, N.I.H., Extramural]. Psychological Review, 115, 186-198.
23. Jacobs, E. A., & Bickel, W. K. (1999). Modeling drug consumption in the clinic using simulation procedures: demand for heroin and cigarettes in opioid-dependent outpatients. [Clinical Trial Research Support, U.S. Gov't, P.H.S.]. Experimental and Clinical Psychopharmacology, 7, 412-426.
24. Johnson, M. W., & Bickel, W. K. (2006). Replacing relative reinforcing efficacy with behavioral economic demand curves. Journal of the Experimental Analysis of Behavior, 85, 73-93. doi:10.1901/jeab.2006.102-04.
25. Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Wiedemann, K. (2003). Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Archives of General Psychiatry, 60, 92-99. doi:10.1001/archpsyc.60.1.92.
26. Killeen, T. K., Brady, K. T., Gold, P. B., Simpson, K. N., Faldowski, R. A., Tyson, C., & Anton, R. F. (2004). Effectiveness of naltrexone in a community treatment program. Alcoholism, Clinical and Experimental Research, 28, 1710-1717. doi:10.1097/01.ALC.0000145688.30448.2C.
27. Kim, S. G., Kim, C. M., Choi, S. W., Jae, Y. M., Lee, H. G., Son, B.K., Oslin, D. W. (2009). A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl), 201, 611-618. doi:10.1007/s00213-008-1330-5.
28. King, A. C., Volpicelli, J. R., Frazer, A., & O'Brien, C. P. (1997). Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl), 129, 15-22. doi:10.1007/s002130050156.
29. Kranzler, H. R., Modesto-Lowe, V., & Van Kirk, J. (2000). Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology, 22, 493-503. doi:10.1016/S0893133X(99)00135-9.
30. Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001). Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine, 345, 1734-1739. doi:10.1056/NEJMoa 011127.
31. Lagorio, C. H., & Madden, G. J. (2005). Delay discounting of real and hypothetical rewards III: Steady-state assessments, forced-choice trials, and all real rewards. Behavioural Processes, 69, 173-187. doi:10.1016/j.beproc.2005.02.003.
32. Latt, N. C., Jurd, S., Houseman, J., & Wutzke, S. E. (2002). Naltrexone in alcohol dependence: A randomised controlled trial of effectiveness in a standard clinical setting. Medical Journal of Australia, 176, 530-534.
33. Li, T. K., Yin, S. J., Crabb, D. W., O'Connor, S., & Ramchandani, V. A. (2001). Genetic and environmental influences on alcohol metabolism in humans. Alcoholism, Clinical and Experimental Research, 25, 136-144. doi:10.1111/j.1530-0277.2001.tb02138.x.
34. MacKillop, J., Amlung, M. T., Acker, J., & Stojek, M. (2010). Further validation of an alcohol purchase task: Equivalence of versions for hypothetical and actual rewards. Alcoholism: Experimental and Clinical Research 34(Suppl), 48A.
35. MacKillop, J., Amlung, M. T., Murphy, C. M., Acker, J., & Ray, L. A. (Eds.). (in press). A behavioral economic approach to health behavior. Burlington, MA: Jones and Bartlett Publishers, LLC.
36. MacKillop, J., Miranda, R., Jr., Monti, P. M., Ray, L. A., Murphy, J. G., Rohsenow, D. J., Gwaltney, C. J. (2010). Alcohol demand, delayed reward discounting, and craving in relation to drinking and alcohol use disorders. Journal of Abnormal Psychology, 119, 106-114. doi:10.1037/a0017513.
37. MacKillop, J., & Murphy, J. G. (2007). A behavioral economic measure of demand for alcohol predicts brief intervention outcomes. Drug and Alcohol Dependence, 89, 227-233. doi:10.1016/j.drugalcdep.2007.01.002.
38. MacKillop, J., Murphy, J. G., Ray, L. A., Eisenberg, D. T., Lisman, S. A., Lum, J. K., & Wilson, D. S. (2008). Further validation of a cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers. Experimental and Clinical Psychopharmacology, 16, 57-65. doi:10.1037/1064-1297.16.1.57.
39. MacKillop, J., Murphy, J. G., Tidey, J. W., Kahler, C. W., Ray, L. A., & Bickel, W. K. (2009). Latent structure of facets of alcohol reinforcement from a behavioral economic demand curve. Psychopharmacology (Berl), 203, 33-40.
40. MacKillop, J., O'Hagen, S., Lisman, S. A., Murphy, J. G., Ray, L. A., Tidey, J. W., Monti, P. M. (2010). Behavioral economic analysis of cue-elicited craving for alcohol. Addiction, 105, 1599-1607. doi: 10.1111/j.1360-0443.2010.03004.x.
41. Madden, G. J., Raiff, B. R., Lagorio, C. H., Begotka, A. M., Mueller, A. M., Hehli, D. J., & Wegener, A. A. (2004). Delay discounting of potentially real and hypothetical rewards: II. Betweenand withinsubject comparisons. Experimental and Clinical Psychopharmacology, 12, 251-261. doi:10.1037/1064-1297.12.4.251.
42. McCaul, M. E., Wand, G. S., Stauffer, R., Lee, S. M., & Rohde, C. A. (2001). Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology, 25, 537-547. doi:10.1016/S0893-133X(01)00241-X.
43. McGeary, J. E., Monti, P. M., Rohsenow, D. J., Tidey, J., Swift, R., & Miranda, R., Jr. (2006). Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcoholism, Clinical and Experimental Research, 30, 1288-1296. doi:10.1111/j.1530-0277.2006.00156.x.
44. Monti, P. M., & Mackillop, J. (Eds.). (2007). Advances in the treatment of craving for alcohol and tobacco. Amsterdam, The Netherlands: Elsevier Press.
45. Monti, P. M., Rohsenow, D. J., Swift, R. M., Gulliver, S. B., Colby, S. M., Mueller, T. I., Asher, M. K. (2001). Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcoholism, Clinical and Experimental Research, 25, 1634-1647. doi:10.1111/j.1530-0277.2001.tb02170.x.
46. Morris, P. L., Hopwood, M., Whelan, G., Gardiner, J., & Drummond, E. (2001). Naltrexone for alcohol dependence: A randomized controlled trial. Addiction, 96, 1565-1573. doi:10.1046/j.1360-0443.2001.961115654.x.
47. Murphy, J. G., & MacKillop, J. (2006). Relative reinforcing efficacy of alcohol among college student drinkers. Experimental and Clinical Psychopharmacology, 14, 219-227. doi:10.1037/1064-1297.14.2.219.
48. Murphy, J. G., MacKillop, J., Skidmore, J. R., & Pederson, A. A. (2009). Reliability and validity of a demand curve measure of alcohol reinforcement. Experimental and Clinical Psychopharmacology, 17, 396-404. doi:10.1037/a0017684.
49. Murphy, J. G., MacKillop, J., Tidey, J. W., Brazil, L. A., & Colby, S. M. (2011). Validity of a demand curve measure of nicotine reinforcement with adolescent smokers. Drug and Alcohol Dependence, 113, 207-214. doi:10.1016/j.drugalcdep.2010.08.004.
50. O'Connor, S., Morzorati, S., Christian, J., & Li, T. K. (1998). Clamping breath alcohol concentration reduces experimental variance: Application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcoholism, Clinical and Experimental Research, 22, 202-210. doi: 10.1111/j.1530-0277.1998.tb03639.x.
51. O'Malley, S. S., Jaffe, A. J., Chang, G., Schottenfeld, R. S., Meyer, R. E., & Rounsaville, B. (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Archives of General Psychiatry, 49, 881-887. doi:10.1001/archpsyc.1992.01820110045007.
52. O'Malley, S. S., Krishnan-Sarin, S., Farren, C., Sinha, R., & Kreek, M. J. (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitaryadrenocortical axis. Psychopharmacology (Berl), 160, 19-29. doi: 10.1007/s002130100919.
53. Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003). A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology, 28, 1546-1552. doi:10.1038/sj.npp.1300219.
54. Ramchandani, V. A., Bolane, J., Li, T. K., & O'Connor, S. (1999). A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcoholism, Clinical and Experimental Research, 23, 617-623. doi:10.1111/j.1530-0277.1999.tb04163.x.
55. Ray, L. A., Bujarski, S., Chin, P. F., & Miotto, K. (2012). Pharmacogenetics of naltrexone in Asian Americans: A randomized placebo- controlled laboratory study. Neuropsychopharmacology, 37, 445-455.
56. Ray, L. A., Chin, P. F., & Miotto, K. (2010). Naltrexone for the treatment of alcoholism: Clinical findings, mechanisms of action, and pharmacogenetics. CNS & Neurological Disorders Drug Targets, 9, 13-22.
57. Ray, L. A., & Hutchison, K. E. (2004). A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcoholism, Clinical and Experimental Research, 28, 17891795. doi:10.1097/01.ALC.0000148114.34000.B9.
58. Ray, L. A., & Hutchison, K. E. (2007). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A doubleblind placebo-controlled study. Archives of General Psychiatry, 64, 1069-1077. doi:10.1001/archpsyc.64.9.1069.
59. Ray, L. A., Krull, J. L., & Leggio, L. (2010). The effects of naltrexone among alcohol non-abstainers: Results from the COMBINE Study. Frontiers in Psychiatry, 1, 26. doi:10.3389/fpsyt.2010.00026.
60. Ray, L. A., Meskew-Stacer, S., & Hutchison, K. E. (2007). The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. Journal of Studies On Alcohol Drugs, 68, 379-384.
61. Rubio, G., Manzanares, J., Lopez-Munoz, F., Alamo, C., Ponce, G., Jimenez-Arriero, M. A., & Palomo, T. (2002). Naltrexone improves outcome of a controlled drinking program. Journal of Substance Abuse Treat, 23, 361-366. doi:10.1016/S0740-5472(02)00296-9.
62. Rubio, G., Ponce, G., & Manzanares, J. (2002). Naltrexone for alcohol dependence. New England Journal of Medicine, 346, 1329-1331; author reply 1329-1331. doi:10.1056/NEJM200204253461716.
63. Schuh, K. J., Walsh, S. L., & Stitzer, M. L. (1999). Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology, 145, 162-174. doi:10.1007/s002130051045.
64. Singer, J. D. (1998). Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. Journal of Educational and Behavioral Statistics, 24, 323-355.
65. Swift, R. M., Whelihan, W., Kuznetsov, O., Buongiorno, G., & Hsuing, H. (1994). Naltrexone-induced alterations in human ethanol intoxication. American Journal of Psychiatry, 151, 1463-1467.
66. Tidey, J. W., Monti, P. M., Rohsenow, D. J., Gwaltney, C. J., Miranda, R., Jr., McGeary, J. E., Paty, J. A. (2008). Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcoholism, Clinical and Experimental Research, 32, 58-66. doi:10.1111/j.1530-0277.2007.00545.x.
67. Volpicelli, J. R., Alterman, A. I., Hayashida, M., & O'Brien, C. P. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49, 876-880. doi:10.1001/archpsyc.1992.01820110040006.
68. Vuchinich, R. E., & Heather, N. (2003). Choice, behavioral economics, and addiction. Oxford, UK: Pergamon Press.